UNITED STATES

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 8-K 

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 22, 2020

 

Milestone Scientific Inc.

(Exact name of registrant as specified in its charter)

 

Delaware
(State or other jurisdiction
of incorporation)

001-14053
(Commission
File Number)

13-3545623
(IRS Employer
Identification No.)

 

 

425 Eagle Rock Avenue, Suite 403

Roseland, NJ
(Address of principal executive offices)

07068
(Zip Code)

 

Registrant’s telephone number, including area code (973) 535-2717

 

(Former name or former address, if changed since last report.)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name on exchange on which registered

Common Stock

MLSS

NYSE American

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

 

 

 
 

 

Item 8.01     Other Events

 

On May 22, 2020, Milestone Scientific Inc. (the “Company”) issued a press release announcing that the Company regained compliance with the stockholder’s equity requirements under the continued listing standards of the NYSE American LLC. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

 

Item 9.01     Financial Statements and Exhibits

 

 

(d)

Exhibits

 

The following exhibit is filed with this report:

 

 

99.1

Press release dated May 22, 2020 

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Milestone Scientific Inc.
 

 

Dated: May 22, 2020 

By:  

/s/ Joseph D'Agostino

 

 

 

Joseph D’Agostino 

 

 

 

Chief Financial Officer

 

 

 

 

Exhibit 99.1

 

 

Contact:
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020

 

 

Milestone Scientific Regains Compliance with New York Stock Exchange Listing Standards

 

LIVINGSTON, NJ, May 22, 2020 -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today confirms that it regained compliance with the stockholder’s equity requirements under the continued listing standards of the NYSE American LLC (“Exchange”).

 

In November 2018, Milestone Scientific received notice from the Exchange that the Company was not then in compliance with the continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide. On December 20, 2018, the Company submitted a plan to achieve compliance (the “Plan”) by May 20, 2020. The Plan was accepted by the Exchange on January 24, 2019. The Company implemented the Plan, and it received notice from the Exchange on May 20, 2020 that it is now compliant with the continued listing standards.

 

About Milestone Scientific Inc.

 

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone’s proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.

 

Safe Harbor Statement

 

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2019. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

 

# # #